About Us

ImmunoGeneTeqs was established in June 2019 as a Tokyo University of Science venture company with the aim of providing methods to control inflammation and immune intractable diseases based on better genetic analysis technology.

Our company provides contract services for T cell receptor (TCR) repertoireand single cell gene expression (scRNA-seq) analysis while introducing TAS-Seq technology developed by Tokyo University of Science, etc. We hope to contribute to society through the development of clinical test drugs, novel T cell therapies, vaccine therapies, and 1 cell information database. We hope to contribute to society through the development of clinical test drugs, novel T-cell therapies, vaccine therapies, and 1-cell information databases.

About Us

ImmunoGeneTeqs was established in June 2019 as a Tokyo University of Science venture company with the aim of providing methods to control inflammation and immune intractable diseases based on better genetic analysis technology.

Our company provides contract services for T cell receptor (TCR) repertoireand single cell gene expression (scRNA-seq) analysis while introducing TAS-Seq technology developed by Tokyo University of Science, etc. We hope to contribute to society through the development of clinical test drugs, novel T cell therapies, vaccine therapies, and 1 cell information database. We hope to contribute to society through the development of clinical test drugs, novel T-cell therapies, vaccine therapies, and 1-cell information databases.

About Us

ImmunoGeneTeqs was established in June 2019 as a Tokyo University of Science venture company with the aim of providing methods to control inflammation and immune intractable diseases based on better genetic analysis technology.

Our company provides contract services for T cell receptor (TCR) repertoireand single cell gene expression (scRNA-seq) analysis while introducing TAS-Seq technology developed by Tokyo University of Science, etc. We hope to contribute to society through the development of clinical test drugs, novel T cell therapies, vaccine therapies, and 1 cell information database. We hope to contribute to society through the development of clinical test drugs, novel T-cell therapies, vaccine therapies, and 1-cell information databases.

Corporate
Profile

Company Name

ImmunoGeneTeqsCorporation
ImmunoGeneTeqs, Inc.(IGT)

Establishment

June 3, 2019

Capital

12.74 million yen

Location

1F Building 17, Tokyo University of Science, Noda Campus, 2669 Yamazaki, Noda, Chiba 278-0022, Japan

1F Building 17, Tokyo University of Science, Noda Campus, 2669 Yamazaki, Noda, Chiba 278-0022, Japan

Management Team

Yoshimasa Imamura, Representative Director
Kouji Matsushima, Director 
Satoshi Ueha, Director
Shigeyuki Shichino, Director
Noboru Minowa, Director
Kazuo Toyama, Director
Masanobu Naruto, Auditor

Major Clients

The University of Tokyo
Kyoto University
Tohoku University
Hokkaido University
Osaka University
University of Tsukuba
Chiba University
Nagoya University
Kyushu University
University of Toyama
Kanazawa University
Kobe University
Nagasaki University
Keio University
Tokyo Medical and Dental University
Juntendo University
National Institute for Global Health and Medicine

We have experience with many other companies.